staff reporter

The first patient has been dosed in a Phase II trial evaluating Treos' off-the-shelf immunotherapy PolyPEPI1018 and Roche's checkpoint inhibitor Tecentriq. 

News items for the week of June 27, 2022.

In clinical trials, the firm will screen patients for their tumors' nutritional vulnerabilities, and dispense a complete diet to be used alongside drugs.

Sixth Street is providing funds in exchange for future royalties of Ayvakit and the KIT D816V inhibitor BLU-263, while Royalty Pharma inked a similar deal for Gavreto.

With electronic health record and tumor panel sequence data from tens of thousands of cancer cases, researchers tallied relationships between gene alterations and patient outcomes.

A genomic eligibility algorithm developed for the study will allow researchers to match patients to appropriate therapy trials.

Harbinger has teamed up with SCRI's CRO to launch a 10,000-participant study to validate its multi-cancer early detection platform. 

The trial will enroll around 140 patients with advanced solid tumors driven by KRAS variants, including G12A, G12D, G12R, G12S, or G12V.

The companies are advancing the drug through IND-enabling studies, after which GSK will develop the agent in combination with its PARP Inhibitor Zejula.

The autologous CAR T-cell therapy is now available in Europe as a fourth-line option for relapsed or refractory follicular lymphoma patients.